Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals Digital PIC

Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery

Fineline Cube Sep 7, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals

Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Drug

InnoCare Pharma Receives Hong Kong Approval for Tafasitamab in DLBCL

Fineline Cube Dec 28, 2022

China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the...

Company Deals

LeadArt Biotechnologies Raises USD 6 Million in Pre-Series A Round

Fineline Cube Dec 28, 2022

LeadArt Biotechnologies Inc., a chemical proteomics specialist based in Ningbo, has reportedly raised close to...

Company Drug

Simcere Receives NMPA Clearance for SIM0237 Clinical Study

Fineline Cube Dec 28, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced receiving clearance from the National Medical Products...

Company Drug

CStone Pharmaceuticals Publishes Ayvakit Study Results on Oncologist Website

Fineline Cube Dec 28, 2022

China-based CStone Pharmaceuticals (HKG: 2616) has published the results of the China-based bridging NAVIGATOR study...

Company Deals

Biosion Completes Series B Financing Round Led by Guangfa Xinde Investment

Fineline Cube Dec 28, 2022

Biosion, a global, clinical-stage biotech committed to developing antibody-based therapies targeting immune and oncologic diseases,...

Company Medical Device

BGI Genomics Receives ANVISA Approval for Colorectal Cancer Detection Kit

Fineline Cube Dec 28, 2022

China-based genomics giant BGI Genomics Co., Ltd (SHE: 300676) has reported receiving product approval from...

Company Deals

InflaRx and Staidson Amend Deal to Advance Vilobelimab Regulatory Filing in China

Fineline Cube Dec 28, 2022

Germany-based biopharma InflaRx N.V. (Nasdaq: IFRX) has revealed an amendment to its underlying deal with...

Company Drug

Elpiscience Receives IND Approval for ES014 in China

Fineline Cube Dec 27, 2022

Shanghai-based Elpiscience Biopharmaceuticals Inc. has announced receiving Investigational New Drug (IND) approval in China to...

Company Deals

Ablaze Pharma and Yonghe Partner for Targeted Radiotherapy Development

Fineline Cube Dec 27, 2022

China-based Ablaze Pharma and Yonghe Pharmaceutical have struck a partnership agreement for the research and...

Company Drug

InnoCare Pharma’s Orelabrutinib Placed on Partial Clinical Hold by FDA

Fineline Cube Dec 27, 2022

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that the US FDA has placed...

Company Drug

Hainan Poly Pharm Receives FDA Approval for Generic Lincomycin

Fineline Cube Dec 27, 2022

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving marketing approval from the...

Company Drug

Innovent Biologics’ GFH925 Receives Breakthrough Therapy Designation

Fineline Cube Dec 27, 2022

China’s Center for Drug Evaluation (CDE) website indicates that China-based Innovent Biologics (HKG: 1801) has...

Policy / Regulatory

Sichuan Healthcare Security Administration Announces VBP for Oral Implant Systems

Fineline Cube Dec 27, 2022

The Sichuan Provincial Healthcare Security Administration has released a notification regarding the inter-provincial alliance volume-based...

Company Drug

Junshi Biosciences’ PD-1 Inhibitor Tuoyi Faces FDA Review Delay

Fineline Cube Dec 27, 2022

Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that they have not received...

Company Drug

Huadong Medicine’s Lanluma V and X Approved for Use in Hainan

Fineline Cube Dec 27, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving approval from the Hainan Medical...

Company Drug

Antengene and MSD Collaborate on Global Clinical Study for ATG-037

Fineline Cube Dec 27, 2022

China-based Antengene Corporation Limited (HKG: 6996) has announced a global clinical collaboration with Merck, Sharp...

Company Drug

IASO Biotherapeutics Receives FDA Approval for CT103A IND Application

Fineline Cube Dec 27, 2022

China-based IASO Biotherapeutics has announced approval from the US FDA for an Investigational New Drug...

Company Deals

Shenzhen Würzburg Dynamics Raises RMB 100 Million in Series A Financing Round

Fineline Cube Dec 27, 2022

China-based Shenzhen Würzburg Dynamics has reportedly raised RMB 100 million (USD 14.36 million) in a...

Company Deals

AcornMed Raises RMB 200 Million in Series B Financing Led by Yikai Venture Capital

Fineline Cube Dec 27, 2022

AcornMed, a tumor precision medicine specialist based in Beijing, has reportedly raised RMB 200 million...

Company Drug

CSPC’s NBL-020 Receives FDA IND Approval for Advanced Solid Tumors

Fineline Cube Dec 26, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving Investigational New Drug (IND) approval...

Posts pagination

1 … 633 634 635 … 717

Recent updates

  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
  • Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate
  • Clinical‑Stage Biopharma Revelyx Bio Launches with Exclusive Global License for YY003 – Ready‑to‑Use Recombinant Botulinum Toxin Type A
  • Eton Pharmaceuticals Licenses Auson’s Timolol Gel ASN001 for North America – Potential First Topical Therapy for Infantile Hemangioma in the U.S.
  • China Medical System Licenses Leios Therapeutics’ Injectable Fat‑Reduction Therapy 10XB‑101 in Greater China, Alongside Strategic Equity Investment
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System

Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Company Deals

Clinical‑Stage Biopharma Revelyx Bio Launches with Exclusive Global License for YY003 – Ready‑to‑Use Recombinant Botulinum Toxin Type A

Company Deals

Eton Pharmaceuticals Licenses Auson’s Timolol Gel ASN001 for North America – Potential First Topical Therapy for Infantile Hemangioma in the U.S.

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.